157 related articles for article (PubMed ID: 29752021)
1. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
[TBL] [Abstract][Full Text] [Related]
2. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M
Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011
[TBL] [Abstract][Full Text] [Related]
5. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity.
Mukhopadhaya A; Mendecki J; Dong X; Liu L; Kalnicki S; Garg M; Alfieri A; Guha C
Cancer Res; 2007 Aug; 67(16):7798-806. PubMed ID: 17699785
[TBL] [Abstract][Full Text] [Related]
6. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
7. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells.
Brusa D; Migliore E; Garetto S; Simone M; Matera L
Prostate; 2009 Sep; 69(12):1343-52. PubMed ID: 19496055
[TBL] [Abstract][Full Text] [Related]
10. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.
Ricupito A; Grioni M; Calcinotto A; Hess Michelini R; Longhi R; Mondino A; Bellone M
Cancer Res; 2013 Jun; 73(12):3545-54. PubMed ID: 23539449
[TBL] [Abstract][Full Text] [Related]
11. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
12. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
16. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
17. Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy.
Orange DE; Jegathesan M; Blachère NE; Frank MO; Scher HI; Albert ML; Darnell RB
Prostate Cancer Prostatic Dis; 2004; 7(1):63-72. PubMed ID: 14999241
[TBL] [Abstract][Full Text] [Related]
18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
19. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
Nam GH; Lee EJ; Kim YK; Hong Y; Choi Y; Ryu MJ; Woo J; Cho Y; Ahn DJ; Yang Y; Kwon IC; Park SY; Kim IS
Nat Commun; 2018 Jun; 9(1):2165. PubMed ID: 29867097
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
